President Biden and Senator Sanders pen an op-ed criticizing weight loss and diabetes drug prices. Caroline Woods talks about what this means for weight loss stocks like Eli Lilly (LLY). She talks about how the op-ed mentions that Big Pharma will claim that reducing prices would drive down innovation, but that may not be the case.